Ranitidine Hydrochloride/Bismuth Potassium Citrate/Sucralfate

盐酸雷尼替丁/枸橼酸铋钾/硫糖铝

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRanitidine Hydrochloride/Bismuth Potassium Citrate/Sucralfate
Drug Alias Name盐酸雷尼替丁+硫糖铝+枸橼酸铋钾Ranitidine/Sucralfate/Tripotassium DicitratobismuthateRanitidine Hydrochloride+Sucralfate+Tripotassium Dicitratobismuthate雷尼替丁/硫糖铝/枸橼酸铋钾Ranitidine Hydrochloride-Sucralfate-Tripotassium Dicitratobismuthate +[17] 
ClassificationSmall molecules
Mechanisms of ActionHistamine H2 receptor antagonists
TargetsHistamine H2 receptor
Therapy Area/IndicationsStomach Ulcer
Global Approved IndicationsStomach Ulcer
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2012/11/01
Country/TerritorySouth Korea
CombinationsYes Ranitidine HydrochlorideBismuth Potassium CitrateSucralfate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDaewoong Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaewoong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsStomach Ulcer
Inactive IndicationsN/A

Other Information

ATC CodeA02B
Related LinksN/A